Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients

Eur J Pharmacol. 2006 May 1;536(3):219-22. doi: 10.1016/j.ejphar.2006.03.007. Epub 2006 Mar 14.


Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans after human lung transplantation. AJRCCM. 166, 440-444.]. This review summarizes the literature to date on Pirfenidone in the setting of transplantation, and those studies pertinent to the mechanisms of organ rejection and possible use of Pirfenidone in transplantation patients.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Bronchiolitis Obliterans / etiology
  • Bronchiolitis Obliterans / prevention & control*
  • Humans
  • Lung Transplantation / adverse effects*
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Pyridones / therapeutic use*
  • Transplantation, Homologous


  • Anti-Inflammatory Agents, Non-Steroidal
  • Pyridones
  • pirfenidone